Medidata provides data and analytics tools for clinics and
medical device companies and Dassault hopes to expand its footprint in the fast-growing
life sciences market with the help of this acquisition.
Bernard Charles, CEO, Dassault Systemes said, “Medidata’s leading position in clinical trials complements our life sciences solutions on the 3DEXPERIENCE collaborative platform. Medidata’s recent expansion into real world evidence and analytics coupled with the power of modeling and simulation demonstrates how the virtual world will catalyse the next generation of patient-inclusive therapeutics.”
Medidata’s shares have gained 44% thus far this year. The stock was down 3.2% in morning hours on Wednesday.
ADVERTISEMENT